Currently, there are 89.83M common shares owned by the public and among those 74.85M shares have been available to trade.
Insiders at the company have transacted a total of 1 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 13,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 13.86, up 7.36%. The company’s stock has a 5-day price change of 8.72% and 20.25% over the past three months. AVDL shares are trading -2.83% year to date (YTD), with the 12-month market performance up to 44.73% higher. It has a 12-month low price of $8.00 and touched a high of $17.24 over the same period. AVDL has an average intraday trading volume of 1.03 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.72%, -3.54%, and 3.74% respectively.
Institutional ownership of Avadel Pharmaceuticals plc ADR (NASDAQ: AVDL) shares accounts for 56.16% of the company’s 89.83M shares outstanding.
It has a market capitalization of $1.23B and a beta (3y monthly) value of 1.55. The earnings-per-share (ttm) stands at -$2.02. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.15% over the week and 4.73% over the month.
Analysts forecast that Avadel Pharmaceuticals plc ADR (AVDL) will achieve an EPS of -$0.29 for the current quarter, -$0.22 for the next quarter and -$0.41 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.34 while analysts give the company a high EPS estimate of -$0.23. Comparatively, EPS for the current quarter was -$0.46 a year ago. Earnings per share for the fiscal year are expected to increase by 21.88%, and 75.94% over the next financial year. EPS should grow at an annualized rate of 15.00% over the next five years, compared to 4.78% over the past 5-year period.
Looking at the support for the AVDL, a number of firms have released research notes about the stock. UBS stated their Buy rating for the stock in a research note on February 06, 2024, with the firm’s price target at $21. Jefferies coverage for the Avadel Pharmaceuticals plc ADR (AVDL) stock in a research note released on November 30, 2022 offered a Buy rating with a price target of $11. Jefferies was of a view on August 10, 2022 that the stock is Hold, while Craig Hallum gave the stock Buy rating on July 28, 2022, issuing a price target of $15.50- $12. Stifel on their part issued Hold rating on May 26, 2022.
